Fig. 7From: Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancersOverall tumor response in PDTC specimens. A Samples from all patient specimen and specimen expressing CEACAM5 with colorectal cancer, B gastric cancer, and C lung cancer. CEACAM5-positive specimens according to immunohistochemistry are shown in the left-hand panels, while specimens expressing high levels of CEACAM5 are shown in the right-hand panels. A summary of the mean values of the normalized tumor responses is given in Additional file 1: Table S4. D HE stainings of one representative colon cancer specimen is given, together with the immunofluorescent staining against CD3 and CD68, counterstained with DAPI. HE bar = 250 µm; immunofluorescence bar = 50 µmBack to article page